Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.

Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ.

Haemophilia. 2019 Apr 17. doi: 10.1111/hae.13758. [Epub ahead of print]

PMID:
30993845
2.

Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition.

Triller D, Myrka A, Gassler J, Rudd K, Meek P, Kouides P, Burnett AE, Spyropoulos AC, Ansell J.

Jt Comm J Qual Patient Saf. 2018 Nov;44(11):630-640. doi: 10.1016/j.jcjq.2018.04.015. Epub 2018 Jul 24.

PMID:
30064950
3.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

4.

Prospective analysis of bleeding events in left ventricular assist device patients.

Sherazi S, Kouides P, Francis C, Lowenstein CJ, Refaai M, Conley G, Johnson BA, Muchnik E, Lien S, Massey HT, Alexis JD.

Int J Artif Organs. 2018 May;41(5):269-276. doi: 10.1177/0391398818762353. Epub 2018 Mar 22.

PMID:
29562808
5.

Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.

Kouides PA.

Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082. eCollection 2017 Apr 25.

6.

The spectrum of bleeding in women and girls with haemophilia B.

Staber J, Croteau SE, Davis J, Grabowski EF, Kouides P, Sidonio RF Jr.

Haemophilia. 2018 Mar;24(2):180-185. doi: 10.1111/hae.13376. Epub 2017 Nov 27. Review.

PMID:
29178325
7.

Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study.

Abou-Ismail MY, Ogunbayo GO, Secic M, Kouides PA.

Am J Hematol. 2018 Feb;93(2):232-237. doi: 10.1002/ajh.24962. Epub 2017 Nov 17.

8.

Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.

Srivaths LV, Zhang QC, Byams VR, Dietrich JE, James AH, Kouides PA, Kulkarni R; Hemophilia Treatment Centers Network Investigators.

Haemophilia. 2018 Jan;24(1):63-69. doi: 10.1111/hae.13330. Epub 2017 Sep 5.

9.

Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.

Kouides P, Wawra-Hehenberger K, Sajan A, Mead H, Simon T.

Transfusion. 2017 Oct;57(10):2390-2403. doi: 10.1111/trf.14241. Epub 2017 Jul 10.

PMID:
28691218
10.

Feasibility of the Von Willebrand disease PREVENT trial.

Ragni MV, Machin N, James AH, Seaman CD, Malec LM, Kessler CM, Konkle BA, Kouides PA, Neff AT, Philipp CS, Brooks MM.

Thromb Res. 2017 Aug;156:8-13. doi: 10.1016/j.thromres.2017.05.022. Epub 2017 May 25.

PMID:
28577390
11.

Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.

Singal M, Kouides PA.

Drugs Today (Barc). 2016 Dec;52(12):653-664. doi: 10.1358/dot.2016.52.12.2570978. Review.

PMID:
28276537
12.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
13.

Efficacy and safety of a VWF/FVIII concentrate (wilate® ) in inherited von Willebrand disease patients undergoing surgical procedures.

Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM; Wonders Study Investigators.

Haemophilia. 2017 Mar;23(2):264-272. doi: 10.1111/hae.13106. Epub 2016 Dec 27.

14.

The scope and value of an anticoagulation stewardship program at a community teaching hospital.

Wychowski MK, Ruscio CI, Kouides PA, Sham RL.

J Thromb Thrombolysis. 2017 Apr;43(3):380-386. doi: 10.1007/s11239-016-1455-z.

PMID:
27878507
15.

Present day management of inherited bleeding disorders in pregnancy.

Kouides PA.

Expert Rev Hematol. 2016 Oct;9(10):987-95. doi: 10.1080/17474086.2016.1216312. Epub 2016 Aug 2. Review.

PMID:
27459638
16.

Use of donated clotting factors for surgeries on haemophilic patients in a resource-constrained country: a kind donor, good outcome, change of practice and future directions.

Poudyal BS, Shrestha GS, Tuladhar S, Gyawali B, Sedain G, Battajo R, Maskey P, Paudyal S, Regmi S, Rc DR, Kouides P.

Haemophilia. 2016 Sep;22(5):e453-5. doi: 10.1111/hae.13017. Epub 2016 Jun 28. No abstract available.

PMID:
27353411
17.

Von Willebrand factor for menorrhagia: a survey and literature review.

Ragni MV, Machin N, Malec LM, James AH, Kessler CM, Konkle BA, Kouides PA, Neff AT, Philipp CS, Brambilla DJ.

Haemophilia. 2016 May;22(3):397-402. doi: 10.1111/hae.12898. Epub 2016 Feb 4. Review.

18.

Developing a multidisciplinary Young Women's Blood Disorders Program: a single-centre approach with guidance for other centres.

Zia A, Lau M, Journeycake J, Sarode R, Marshall J, De Simone N, Wilson E, Winborn A, Kouides P.

Haemophilia. 2016 Mar;22(2):199-207. doi: 10.1111/hae.12836. Epub 2016 Jan 29.

PMID:
26822547
19.

Validation Study of the Composite Score to Identify Von Willebrand Disease in Children.

Malec LM, Moore CG, Bennett CM, Yee DL, Kerlin BA, Witmer CM, Kulkarni R, Gupta S, Gunawardena S, Kouides PA, Brown D, Ragni MV.

J Pediatr Hematol Oncol. 2016 Mar;38(2):139-42. doi: 10.1097/MPH.0000000000000460.

PMID:
26535774
20.

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B.

Blood. 2015 Oct 22;126(17):2038-46. doi: 10.1182/blood-2015-02-629873. Epub 2015 Aug 3.

Supplemental Content

Loading ...
Support Center